Research and Development

Clinical research performed over the past few years continues to show benefits arising from medical marijuana. Presently there are in excess of 1 million US “medical marijuana” patients and an increasing number of physicians in the US are writing prescriptions (sometimes called a recommendation, depending upon the State) for medicinal cannabis. Smoked cannabis aside, new extracts and compounds from the industrial hemp plant have been developed and adopted by the cannabis community. Cannabidiol, one of the most prevalent non-psycho-active cannabinoids has shown significant health and wellness benefits – potentially more beneficial than cannabis and THC.

One of science’s newest and most exciting discovery’s is that of the endocannabinoid system. Part of all mammalian life (yes, including us humans!) this system regulates such functions as eating, sleeping, memory, relaxation, the immune system and is a large nerve communication network. Cells within our bodies have receptor sites for these cannabinoids so they are meant to be part of the human dietary experience – many researchers now postulate there may be a cannabinoid deficiency syndrome. The CB1 receptor sites are primarily found in the brain, while the CB2 receptors are found in the internal organs and digestive tract. Phyto-cannabinoids (plant based cannabinoids) seem to act in a similar manner as to the human produced endocannabinoids – thus we may be able to supplement our diets with these plant based cannabinoids.




Medical Marijuana Research by Disorder:

Alzheimer's Disease
Anxiety Disorder
Cardiovascular Disease
Central Nervous System Disorder
Crohn's Disease

Early Morning Disorder
Heroin Addiction
Liver Disorders
Multiple Sclerosis
Nausea and Pain

Neurological Disorder
Parkinson's Disease
Retinal Damage

If there is any relevant information that you feel we should share with our readers or with Medical Marijuana Inc., please email us at This email address is being protected from spambots. You need JavaScript enabled to view it. and we will be sure to make additional prudent information available to our shareholders, partners and the public.